Cato Laurencin, MD, PhD, was appointed as independent director of Alkermes' board of directors, according to a Nov. 19 news release.
Dr. Laurencin is a professor and Van Dusen Distinguished Endowed Professor of orthopedic surgery at University of Connecticut School of Medicine in Farmington. He received his medical degree from and completed his residency at Harvard Medical School in Boston.
He will be the sixth new independent director of Alkermes' board since 2019.
"Dr. Laurencin brings to the Alkermes Board significant experience across a wide range of medical and scientific disciplines, a focus on public health that is consistent with the company's core values and business strategy, strong administrative skills, and a keen understanding of how scientific innovation has the potential to drive shareholder value creation," Richard Pops, Alkermes CEO and chair, said in the release.
Alkermes is a biopharmaceutical company focusing on neuroscience and oncology.